If someone told me that I could use samumed, a fairly complicated drug lacking long-term safety data, to achieve similar results as minoxidil, a mild vasodilator, I think I would just continue using minoxidil.
It doesn't work as a mild vasodilator.
It doesn't work as a mild vasodilator.
100% agreed. If they found something worth showing on high norwoods, that must mean that this should be a functional solution for gaining back atleast a norwood or getting somewhat significant density. I'm extremely optimistic about this.Looking at the size/importance of the conference, and the fact that they tested on high Norwood scales and seem to have gotten significant results, makes me feel pretty good about this.
We'll see in a day.
The findings are consistent with preclinical in vivo animal models, in which SM04554 has been shown to generate new hair follicles and increase hair count.
Just out of curiosity has Samumed successfully brought any of their products to commercialization?
I looked on their website and didn't see anything regarding that.
I imagine if it's very promising, big pharma will be wanting to pick the low hanging fruit as they say. They are sitting on mountains of cash after playing low key with 20 and 30 year patent protections on old drug discoveries.
Just out of curiosity has Samumed successfully brought any of their products to commercialization?
I looked on their website and didn't see anything regarding that.
yeah too long thb,20 years for patent exclusivity is WAY too long.
Just out of curiosity has Samumed successfully brought any of their products to commercialization?
I looked on their website and didn't see anything regarding that.
BTW, this is one of the things about SM04554 that concerns me. The company, Samumed, is new to this whole process and so maybe they
are making mistakes and maybe they are sending positive signals even though their results are poor. For example, if the experienced
Merck was bringing SM04554 to market and their initial phase 2 demonstrated poor results then they would pull the plug on their
supplemental phase 2 but with Samumed being new to all of this they may not get it that if their initial phase 2 was bad they
should pull the plug on their supplemental phase 2. So it is possible that all of the positive signals coming from Samumed
may be the result of them making mistakes due to their inexperience at clinical trials & how to react to stuff therein.
BTW, this is one of the things about SM04554 that concerns me. The company, Samumed, is new to this whole process and so maybe they
are making mistakes and maybe they are sending positive signals even though their results are poor. For example, if the experienced
Merck was bringing SM04554 to market and their initial phase 2 demonstrated poor results then they would pull the plug on their
supplemental phase 2 but with Samumed being new to all of this they may not get it that if their initial phase 2 was bad they
should pull the plug on their supplemental phase 2. So it is possible that all of the positive signals coming from Samumed
may be the result of them making mistakes due to their inexperience at clinical trials & how to react to stuff therein.
The day has come. Is anyone here attending?
That would be plain common sense to me and whether they have experience or not they're obviously bright people to be doing what they are doing so I think they would pull the plug if they didn't see results nevermind go on display at a world conference to present those results.
When I asked the question of whether they had a project reach commercialization I wasn't asking it in a negative way. I'm sure there are plenty of companies that develop treatments and then sell them off to big pharma i.e. they stick to what they know best which is development rather than get themselves in trouble entering a game they don't understand --> distribution/commercialization.
Then again you could be totally right no one knows anything until it happens - this is all speculation. Hopefully we get good news tomorrow.